Heart failure drug put to the test in Real-World german patients
NCT ID NCT06486844
Summary
This study looked back at health records to see how well a heart failure medicine called vericiguat works for people in everyday German medical care. Researchers analyzed data from 500 adults with chronic heart failure who were newly prescribed the drug between 2021 and 2023. The main goal was to collect real-world information on death rates and hospital stays after patients started this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bayer
Wuppertal, 42096, Germany
Conditions
Explore the condition pages connected to this study.